Literature DB >> 6204681

Hybridoma antibodies to human von Willebrand factor. II. Relative role of intramolecular loci in mediation of platelet adhesion to the subendothelium.

D Meyer, H R Baumgartner, T S Edginton.   

Abstract

Hybridoma antibodies specific for seven independent topographical sites were used to characterize von Willebrand factor (vWF) and to relate the epitopes to functional loci required for vWF-mediated adhesion of platelets to subendothelium and ristocetin-induced platelet aggregation. The capacity of antibodies to influence the adhesion of human platelets to rabbit aortic subendothelium was analysed in annular perfusion chambers. At a high shear rate similar to that of the microcirculation, four monoclonal antibodies inhibited adhesion. In contrast, no inhibition was observed at low shear. Only one of the four antibodies that inhibited platelet adhesion also attenuated ristocetin-cofactor activity (VIIIR:RCo). Conversely, one antibody that inhibited VIIIR:RCo had no effect upon platelet adhesion. These data support the hypothesis that the molecular loci involved in the two biological functions of vWF are not identical. When these conclusions are considered within the context of a spatial map of the vWF protein surface developed by competitive displacement analysis, the epitopes related to platelet adhesion appear to be spaced and differ from those involved in ristocetin-induced platelet-platelet interaction.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6204681     DOI: 10.1111/j.1365-2141.1984.tb02938.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  6 in total

Review 1.  Factor VIII/von Willebrand factor: a multivalent ligand binding to platelets and collagen.

Authors:  M Furlan
Journal:  Blut       Date:  1986-06

2.  A monoclonal antibody recognizes a von Willebrand factor domain within the amino-terminal portion of the subunit that modulates the function of the glycoprotein IB- and IIB/IIIA-binding domains.

Authors:  I Tornai; J Arnout; H Deckmyn; K Peerlinck; J Vermylen
Journal:  J Clin Invest       Date:  1993-01       Impact factor: 14.808

3.  Evidence that a secondary binding and protecting site for factor VIII on von Willebrand factor is highly unlikely.

Authors:  S Layet; J P Girma; B Obert; E Peynaud-Debayle; N Bihoreau; D Meyer
Journal:  Biochem J       Date:  1992-02-15       Impact factor: 3.857

4.  Epitope mapping by cDNA expression of a monoclonal antibody which inhibits the binding of von Willebrand factor to platelet glycoprotein IIb/IIIa.

Authors:  G Piétu; A S Ribba; G Chérel; D Meyer
Journal:  Biochem J       Date:  1992-06-15       Impact factor: 3.857

5.  Comparison of two dimensional immunoelectrophoresis and multimer analysis in the study of von Willebrand factor.

Authors:  M A Howard; A Oates; B G Firkin
Journal:  J Clin Pathol       Date:  1988-03       Impact factor: 3.411

6.  Prevention of occlusive coronary artery thrombosis by a murine monoclonal antibody to porcine von Willebrand factor.

Authors:  D A Bellinger; T C Nichols; M S Read; R L Reddick; M A Lamb; K M Brinkhous; B L Evatt; T R Griggs
Journal:  Proc Natl Acad Sci U S A       Date:  1987-11       Impact factor: 11.205

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.